U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117318) titled 'Rectal NSAIDs With/Without PD Stent for PEP Prevention' on Aug. 05.
Brief Summary: Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stent (PDS) placement were demonstrated to be effective strategyies to reduce PEP incidences, particlularly in high-risk patients for post-ERCP pancreatitis (PEP).
Rectal NSAIDs were easy-to-use and safe, while PDS placement were technically complex a...